Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges
Head & Neck · 2025
DOI: 10.1002/hed.70054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Head & Neck, 2025. Verfasst von Hunter A Holley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Graduate Entry Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine malignancy with rising incidence, influenced by ultraviolet (UV) radiation and Merkel cell polyomavirus (MCPyV).
Methods
This review summarizes recent advances in MCC management, based on an analysis of current literature, focusing on immune checkpoint inhibitors (ICIs), viral status implications, and evolving multimodal treatment strategies.
Results
MCPyV‐positive MCC has a median overall survival (OS) of 6.6 years compared to 1.2 years for virus‐negative cases. The 5‐year OS rate for localized MCC is approximately 50%. Historically, the 5‐year OS for metastatic MCC was ~14%, but has significantly improved with ICIs. First‐line treatment with avelumab achieved a median OS of 20.3 months and a 5‐year OS of approximately 26%. Pembrolizumab demonstrated a median OS of 24.3 months, a median progression‐free survival (PFS) of 9.3 months, and a durable response with a median duration of response (DOR) of 39.8 months.
Conclusion
Despite advances, MCC recurrence rates remain high (16.4% local, 32.1% regional, 9.5% distant), necessitating vigilant long‐term surveillance. Future research should focus on optimizing combination therapies, identifying predictive biomarkers, and refining treatment sequencing to further improve survival and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Graduate Entry Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.
- Department of Otorhinolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland.
- Department of Otolaryngology Head and Neck Surgery, RCSI, Dublin, Ireland.
- Department of Plastic Surgery, Beaumont Hospital, Dublin, Ireland.
- St. Luke's Radiation Oncology Network, Dublin, Ireland.
- Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland.
ORCID-Profile: Hunter A Holley
Zitieren
APA
Holley, H. A., Lyons, M., O'Sullivan, B., Shine, N., Woods, R., McArdle, O., & O'Neill, J. P. (2025). Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges. Head & Neck. https://doi.org/10.1002/hed.70054
Vancouver
Holley HA, Lyons M, O'Sullivan B, Shine N, Woods R, McArdle O, et al. Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges. Head & Neck. 2025. doi:10.1002/hed.70054
BibTeX
@article{Holley2025,
author = {Holley, Hunter A and Lyons, Maria and O'Sullivan, Barry and Shine, Neville and Woods, Robbie and McArdle, Orla and O'Neill, James Paul},
title = {Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.70054}
}
EUVIMED